Symbols

HRTX

Heron Therapeutics·NASDAQ

--(--)

HRTX fundamentals

HRTX Q4 2025 Earnings

Heron Therapeutics (HRTX) released its earnings on Feb 26, 2026: revenue was 40.59M (YoY -0.47%), beat estimates; EPS was -0.02 (YoY -200.00%), met estimates.

Revenue / YoY

40.59M

-0.47%

EPS / YoY

-0.02

-200.00%

Report date

Feb 26, 2026

HRTX Earnings Call Summary for Q4,2025

Revenue Growth: 2025 net product sales of $154.9 million, with ZYNRELEF up 48% YoY and APONVIE up 97% YoY.
EBITDA Performance: Adjusted EBITDA of $14.7 million, doubling prior year and exceeding guidance.
Acute Care Momentum: Q4 2025 Acute Care portfolio grew 57% YoY, driven by CrossLink IGNITE, VAN, and J-Code initiatives.
Strategic Investments: 2026 focus on high-opportunity geographies, targeting EBITDA of $10-$20 million despite near-term growth investments.
Regulatory Tailwinds: NOPAIN Act and APONVIE guidelines to support long-term adoption and revenue acceleration.

Earnings

EPS

Revenue

Revenue & Expenses

HRTX has released its 2025 Q4 earnings report, with revenue of 40.59M, reflecting a YoY change of -0.47%, and net profit of -2.95M, showing a YoY change of -180.64%. The Sankey diagram below clearly presents HRTX's revenue sources and cost distribution.

Key Indicators

Heron Therapeutics (HRTX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Heron Therapeutics (HRTX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Heron Therapeutics (HRTX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Heron Therapeutics (HRTX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown